Back to News
Market Impact: 0.35
Parabilis Medicines Reports 72% Response Rate For Zolucatetide In Desmoid Tumors; Stock Down
Source: Nasdaq
Healthcare & Biotech
Parabilis Medicines reported updated Phase 1/2 data indicating that investigational zolucatetide showed encouraging efficacy and a favorable safety and tolerability profile in patients with desmoid tumors. The results were presented at an event; the provided article excerpt contains no numerical efficacy or safety data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PBLS0.70
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results